Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home

Lucas, Mary; Hugh-Jones, Ken; Welby, Angela; Misbah, Siraj; Spaeth, Peter; Chapel, Helen (2010). Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. Journal of clinical immunology, 30 Suppl 1, S84-S89. New York, N.Y.: Springer 10.1007/s10875-010-9400-y

Full text not available from this repository. (Request a copy)

The Oxford Programme for Immunomodulatory Immunoglobulin Therapy has been operating since 1992 at Oxford Radcliffe Hospitals in the UK. Initially, this program was set up for patients with multifocal motor neuropathy or chronic inflammatory demyelinating poly-neuropathy to receive reduced doses of intravenous immunoglobulin (IVIG) in clinic on a regular basis (usually every 3 weeks). The program then rapidly expanded to include self-infusion at home, which monitoring showed to be safe and effective. It has been since extended to the treatment of other autoimmune diseases in which IVIG has been shown to be efficacious.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Späth, Peter Julius

ISSN:

0271-9142

Publisher:

Springer

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

08 Jun 2016 10:20

Publisher DOI:

10.1007/s10875-010-9400-y

PubMed ID:

20387103

Web of Science ID:

000278622300017

URI:

https://boris.unibe.ch/id/eprint/890 (FactScience: 201183)

Actions (login required)

Edit item Edit item
Provide Feedback